Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.
解锁市场时间线与信号动态
最近 90 天内有 17 个信号。
该公司进入各个市场的顺序 — 从最早到最新
28 active postings
Government & Reimbursement Manager
注册以查看完整信号动态
Masimo 的国际扩张与竞争对手的对比情况
Masimo你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Masimo你 | 7 | 2 | +29% | 16 | 31 |
Area Clinical Resource Manager
查看职位Irvine, CA · 4天前
Customer Service Representative
查看职位Irvine, CA · 上周
Manager, OEM Product Development
查看职位Irvine, CA · 上周
Study Finds That When Patients Decline, Respiratory Changes Often Come First
进行中
Patient deterioration often begins with respiratory compromise
进行中
Learn how early detection of respiratory changes can support patient safety
进行中美国国际贸易委员会裁定Apple重新设计的Watch Series 9和Ultra 2不侵犯Masimo的血氧监测专利,拒绝进口禁令请求。
丹纳赫报告生物加工订单激增30%,第一季每股收益增长10%,但将呼吸产品收入预测下调1.5亿美元,同时维持3-6%有机增长展望。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Masimo 的业务、市场和增长信号的快速解答。
